Related Experiment Video
Updated: Feb 11, 2026

RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue
Published on: August 2, 2014
Antibody fusion proteins with human ribonucleases 1 to 8
Xenia Wezler1, Stefan Dübel1, Thomas Schirrmann2
1Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, 38106 Braunschweig, Germany.
Abstract:
ImmunoRNases combine tumor targeting by antibodies with the cytotoxic action of ribonucleases from the RNase A superfamily. This study investigated for the first time all catalytic active human RNase A family members (1 to 8) as effector components of antibody fusion proteins. ImmunoRNase fusion proteins were constructed using the CD30-specific bivalent recombinant scFv-Fc antibody SH313-B5. Production of the resulting entirely human immunoRNases 1 to 8 was done in mammalian cells by secretion of active forms. The immunoRNases mediated CD30-specific cell binding and showed ribonucleolytic activity. Interestingly, immunoRNases 1 and 2 were active in the presence of up to 5-/20-fold molar excess of the pancreatic RNase inhibitor (RI), which is supposed to efficiently inhibit all human RNase A activity. ImmunoRNases 3, 4, 6 and 7 were only inhibited by several fold molar excess of RI, whereas immunoRNases 5 and 8 were already completely inactive at equimolar RI concentrations. Compared to free RNases, activity and RI sensitivity were not significantly changed by antibody fusion or dimerisation. ImmunoRNase3 and 5 mediated tumor growth inhibition at low nanomolar concentrations. Anti-tumor activity was antigen-specific and did not show any correlation with ribonucleolytic activity or RI sensitivity.
Insights
This study explored human ribonuclease (RNase) A family members as cancer-fighting immunoRNases. Some immunoRNases showed potent, antigen-specific tumor growth inhibition, independent of their RNase activity or inhibitor sensitivity.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- ImmunoRNases leverage antibody-mediated tumor targeting and cytotoxic ribonuclease (RNase) activity.
- Human RNase A superfamily members are potential candidates for immunoRNase development.
Purpose of the Study:
- To investigate all catalytic active human RNase A family members (1-8) as effector components in antibody fusion proteins.
- To evaluate the CD30-specific binding, ribonucleolytic activity, and tumor growth inhibition of novel immunoRNases.
Main Methods:
- Construction of immunoRNase fusion proteins using a CD30-specific antibody (SH313-B5).
- Production of fully human immunoRNases in mammalian cells.
- Assessment of enzyme activity in the presence of pancreatic RNase inhibitor (RI).
- Evaluation of antigen-specific anti-tumor activity and tumor growth inhibition in vitro.
Main Results:
- All generated immunoRNases exhibited CD30-specific binding and ribonucleolytic activity.
- ImmunoRNases 1 and 2 displayed resistance to RNase inhibitor (RI), while others showed varying sensitivity.
- Antibody fusion or dimerization did not significantly alter RNase activity or RI sensitivity.
- ImmunoRNases 3 and 5 demonstrated potent, antigen-specific tumor growth inhibition at nanomolar concentrations.
Conclusions:
- Human RNase A family members can be effectively engineered into functional immunoRNases.
- Anti-tumor efficacy of immunoRNases is antigen-specific and not directly correlated with ribonucleolytic activity or RI sensitivity.
- Certain immunoRNases show promising therapeutic potential for CD30-positive malignancies.
Related Concept Videos
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Tagging and Fusion Proteins
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
SNAREs and Membrane Fusion
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
Role of Proteins in the Human Body
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

